Home » Stocks » Kazia Therapeutics

Kazia Therapeutics Limited (KZIA)

Stock Price: $5.95 USD 0.17 (2.94%)
Updated Oct 20, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 68.51M
Revenue (ttm) 1.10M
Net Income (ttm) -10.27M
Shares Out 11.51M
EPS (ttm) -0.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 20, 2020
Last Price $5.95
Previous Close $5.78
Change ($) 0.17
Change (%) 2.94%
Day's Open 5.64
Day's Range 5.64 - 6.14
Day's Volume 60,936
52-Week Range 2.47 - 9.74

More Stats

Market Cap 68.51M
Enterprise Value 64.69M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 11.51M
Float n/a
EPS (basic) n/a
EPS (diluted) -0.92
FCF / Share -0.98
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 22,214
Short Ratio 0.25
Short % of Float n/a
Beta 2.13
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 62.17
PB Ratio 7.66
Revenue 1.10M
Operating Income -6.13M
Net Income -10.27M
Free Cash Flow -4.73M
Net Cash 3.83M
Net Cash / Share 0.33
Gross Margin 100.00%
Operating Margin -555.78%
Profit Margin -656.20%
FCF Margin -429.01%
ROA -34.45%
ROE -88.05%
ROIC -515.30%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$14.42*
Low
14.4
Current: $5.95
High
14.4
Target: 14.42
*Average 12-month USD price target from 1 stock analysts.

Financial Performance

Financial numbers in millions AUD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue1.5713.118.814.072.840.431.732.372.321.79
Revenue Growth-88.06%48.75%116.46%43.24%562.47%-75.2%-27.13%2.24%29.65%-
Gross Profit1.5713.118.814.072.840.431.732.372.321.79
Operating Income-8.70-2.40-10.87-11.59-6.94-6.31-1.38-1.47-5.32-15.80
Net Income-10.27-6.04-10.67-12.16-7.14-7.47-0.79-1.35-9.48-15.25
Shares Outstanding48.4148.3342.9742.3116.8613.8310.382.042.042.04
Earnings Per Share-1.79-1.25-0.23-0.28-2.99-4.76-1.32-1.44-5.23-12.10
Operating Cash Flow-6.71-8.66-11.44-11.98-5.76-5.71-8.80-7.35-8.70-16.61
Capital Expenditures---0.01-0.52-0.09-0.030.140.010.29-0.01
Free Cash Flow-6.71-8.66-11.45-12.50-5.85-5.74-8.66-7.34-8.42-16.62
Cash & Equivalents5.435.9614.4633.4544.372.502.748.356.0215.13
Total Debt-----2.711.42---
Net Cash / Debt5.435.9614.4633.4544.37-0.211.328.356.0215.13
Assets21.1828.1835.9135.5246.144.665.758.9912.7319.29
Liabilities6.988.9310.571.591.783.251.713.878.316.11
Book Value14.2019.2425.3433.9344.671.514.043.484.2311.19
Numbers in millions AUD, except per-share numbers.

Company Profile

Company Details

Full Name Kazia Therapeutics Limited
CEO James Garner

Stock Information

Ticker Symbol KZIA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: KZIA
IPO Date January 6, 1999

Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.